Related Experiment Videos
Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future
A M de Mattos1, A J Olyaei, W M Bennett
1Division of Nephrology, Hypertension, and Clinical Pharmacology, Oregon Health Sciences University, Portland 97201, USA.
Abstract:
The calcineurin inhibitors cyclosporin A (CsA) and tacrolimus (FK506) are associated with dose- and efficacy-limiting adverse events, including nephrotoxicity, which may diminish their overall benefits for long-term graft survival. Nephrotoxicity is difficult to distinguish from chronic allograft rejection and is a particular problem in the setting of renal transplantation. Minimizing immunosuppressant-induced nephrotoxicity could improve long-term renal allograft survival. However, to obtain significant long-term improvement in renal allograft outcomes, it may be necessary to adopt new immunosuppressive regimens that rely less on calcineurin inhibitors. Recipients of other transplanted organs, as well as patients with autoimmune diseases who require immunosuppressant therapy, could also benefit from this change in immunosuppressive drug strategy because their healthy, native kidneys are particularly susceptible to the nephrotoxic effects of CsA and FK506. CsA- and FK506-sparing regimens, which use reduced doses of CsA and FK506 in combination with other nonnephrotoxic immunosuppressants, may be the best current option for reducing nephrotoxicity. The chemical immunosuppressant mycophenolate mofetil (MMF) has been used as part of CsA- and FK506-sparing regimens that provide improved renal function while maintaining adequate immunosuppression. Such regimens should reduce patient morbidity and mortality. Also, because immunosuppressant-induced nephrotoxicity has been associated with significant financial costs, CsA- and FK506-sparing regimens should result in substantial savings in health care costs.
Insights
Calcineurin inhibitors like cyclosporin A and tacrolimus cause kidney damage. New immunosuppressive strategies sparing these drugs can improve transplant outcomes and reduce healthcare costs.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- Calcineurin inhibitors (CsA, FK506) are vital immunosuppressants but cause dose-limiting nephrotoxicity.
- Distinguishing drug-induced kidney damage from transplant rejection is challenging, impacting long-term graft survival.
- Nephrotoxicity affects not only transplant recipients but also patients with autoimmune diseases.
Discussion:
- Minimizing immunosuppressant-induced nephrotoxicity is crucial for improving renal allograft survival.
- New immunosuppressive regimens reducing reliance on calcineurin inhibitors are needed for significant long-term benefits.
- CsA- and FK506-sparing strategies, combining reduced doses with non-nephrotoxic agents, offer a promising approach.
Key Insights:
- Mycophenolate mofetil (MMF) is effective in CsA- and FK506-sparing regimens, maintaining immunosuppression while improving renal function.
- Reduced calcineurin inhibitor use can mitigate kidney damage in transplant recipients and other vulnerable patient groups.
- Implementing these sparing regimens may decrease patient morbidity and mortality.
Outlook:
- Further research into novel, non-nephrotoxic immunosuppressants is warranted.
- Clinical adoption of CsA- and FK506-sparing regimens could lead to substantial healthcare cost savings.
- Optimizing immunosuppressive strategies is key to enhancing long-term outcomes in transplantation and autoimmune disease management.